Document:

exhibit103

  1     Exhibit 10.3  Amended and Restated Employment Agreement      This Amended and Restated Employment Agreement (the “Agreement”), entered into as  of June 3, 2022, is made by and between Clinton Jones (the “Executive”), GoHealth, Inc., a  Delaware corporation (“GoHealth”), and GoHealth Holdings, LLC, a Delaware limited liability  company (the “Partnership” and, together with GoHealth and any of the Affiliates of GoHealth  and the Partnership as may employ the Executive from time to time, and any successor(s) thereto,  the “Company”).      RECITALS      WHEREAS, the Executive currently serves as Chief Executive Officer of the Company  and Co-Chairperson of the Board of Directors of the Company (the “Board”) pursuant to that  certain Employment Agreement with the Company dated July 6, 2020 (the “Prior Agreement”);      WHEREAS, effective as of June 6, 2022 (the “Effective Date”), the Executive shall resign  from his role as Chief Executive Officer;      WHEREAS, the Company desires to assure itself of the continued services of the  Executive following his resignation as Chief Executive Officer by engaging the Executive to  perform services under the terms of this Agreement, which shall supersede the Prior Agreement as  of the Effective Date; and      WHEREAS, the Executive desires to provide services to the Company on the terms herein  provided.         AGREEMENT      NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable  consideration, including the respective covenants and agreements set forth below, the receipt and  sufficiency of which are hereby acknowledged, the parties hereto agree, effective as of the  Effective Date, as follows:     1.  Certain Definitions   (a) “Affiliate” shall mean, with respect to any Person, any other  Person directly   or indirectly controlling, controlled by, or under common control with, such Person where  “control” shall have the meaning given such term under Rule 405 of the Securities Act of 1933, as  amended from time to time.    

 

  2     (b) “Agreement” shall have the meaning set forth in the  preamble hereto.   (c) “Annual Base Salary” shall have the meaning set forth in  Section 3(a).    (d) “Award Agreement” shall have the meaning set forth in  Section 3(b)(iv).    (e) “Board” shall have the meaning set forth in the recitals  hereto.    (f) The Company shall have “Cause” to terminate the  Executive’s employment   hereunder upon:  (i)(A) the willful failure or refusal of the Executive to perform material  responsibilities set forth herein (including Executive’s failure to devote time and attention to his  duties hereunder or failure to regularly attend Board or office meetings); (B) the Executive’s  willful failure to carry out, or comply with, in any material respect any lawful directive of the  Board; (C) dishonesty by the Executive to the Board with respect to any material matter; (D)  misappropriation of funds or property of the Company or any of its Affiliates by the Executive  other than the occasional, customary and de minimis use of Company property for personal  purposes; or (E) a breach by the Executive of this Agreement or other agreement with the Company  (including, without limitation, the Restrictive Covenants Agreement); provided, in the case of each  of clause (i)(A)-(E), if the Board (excluding any Board member as to whom Cause is alleged to  have occurred) determines reasonably and in good faith that such act can reasonably be cured, that  the Company has provided 30 days’ prior written notice to the Executive of such conduct and the  Executive has failed to cure such conduct within such 30 day period in the manner identified by  the Board; (ii) the arrest or charging of the Executive for (A) any felony or (B) a misdemeanor  involving moral turpitude, deceit, dishonesty or fraud, and which is materially detrimental to the  Company and its Affiliates (including material reputational harm); or (iii) the Executive’s  engagement in on-the-job conduct that consists either of gross misconduct or a material violation  of the Company or any of its Affiliates’ written code of ethics or Company policies, and which is  materially detrimental to the Company and its Affiliates (including material reputational harm).   (g) “Code” shall mean the Internal Revenue Code of 1986, as  amended.   (h) “Company” shall have the meaning set forth in the preamble  hereto.   (i) “Date of Termination” shall mean (i) if the Executive’s  employment is   terminated due to the Executive’s death, the date of the Executive’s death; (ii) if the Executive’s  employment is terminated due to the Executive’s Disability, the date determined pursuant to  Section 4(a)(ii); or (iii) if the Executive’s employment is terminated pursuant to Section 4(a)  

 

  3     (iii)(v) either the date indicated in the Notice of Termination or the date specified by the Company  pursuant to Section 4(b), whichever is earlier.   (j) “Disability” shall mean the Executive’s inability to engage  in any   substantial gainful activity by reason of any medically determinable physical or mental impairment  that can be expected to result in death or that can be expected to last for a continuous period of not  less than twelve (12) months.   (k) “Effective Date” shall have the meaning set forth in the  recitals hereto.   (l) “Executive” shall have the meaning set forth in the preamble  hereto.   (m) “Initial SAR Award” shall have the meaning set forth in  Section 3(b)(i)(A).   (n) “Notice of Termination” shall have the meaning set forth in  Section 4(b).   (o) “Person” shall mean any individual, natural person,  corporation (including   any non-profit corporation), general partnership, limited partnership, limited liability partnership,  joint venture, estate, trust, company (including any company limited by shares, limited liability  company or joint stock company), incorporated or unincorporated association, governmental  authority, firm, society or other enterprise, organization or other entity of any nature.   (p) “Plan” shall have the meaning set forth in Section 3(b)(i).   (q) “Prior Agreement” shall have the meaning set forth in the  recitals hereto.   (r) “Pro-Rated Bonus Amount” shall have the meaning set forth  in Section   5(b)(ii).   (s) “Profits Unit Agreement” shall mean the Executive  Common Unit and Profits Unit Agreement by and between the Partnership,  Blizzard Management Feeder, LLC, and the Executive dated October 3, 2019 and  amended July 6, 2020.    (t) “Release” shall have the meaning set forth in Section 5(b).    (u) “Release Expiration Date” shall have the meaning set forth  in Section 21(c).    

 

  4     (v) “Restrictive Covenant Agreement” shall have the meaning  set forth in Section 6.   (w) “SAR Award” shall have the meaning set forth in Section  3(b)(i)(B).   (x) “Section 409A” shall mean Section 409A of the Code and  the Department   of Treasury regulations and other interpretive guidance issued thereunder, including without  limitation any such regulations or other guidance that may be issued after the Effective Date.   (y) “Severance Period” shall have the meaning set forth in  Section 5(b).   (z) “Subsequent SAR Award” shall have the meaning set forth  in Section   3(b)(i)(B).   (aa) “Term” shall have the meaning set forth in Section 2(b).   (bb) “Transition Date” shall mean December 31, 2022.     2.  Employment   (a) In General.  Effective as of the Effective Date, the Company shall employ   the Executive under this Agreement and the Executive shall remain in the employ of the Company  under this Agreement, for the period set forth in Section 2(b), in the position set forth in Section  2(c), and upon the other terms and conditions herein provided.    (b) Term of Employment.  The term of employment under this Agreement (the   “Term”) shall be for the period beginning on the Effective Date and ending on the Transition Date,  unless earlier terminated as provided in Section 4 or extended by a majority of the Board.  For the  avoidance of doubt, the termination of the Executive’s employment on the Transition Date shall  constitute a termination without Cause under Section 4(a)(iv).   (c) Position and Duties.     (i) Effective as of the Effective Date, the Executive  shall resign from   his role as Chief Executive Officer of the Company pursuant to the resignation letter  attached hereto as Exhibit A (the “Resignation Letter”).  Following his resignation as Chief  Executive Officer of the Company and during the Term, the Executive shall be employed  as Executive Chairman of the Company, with responsibilities, duties and authority  customary for such position, subject to direction by the Board, and shall report directly to  the Board.  For the avoidance of doubt, the termination of Executive’s role as Chief  Executive Officer of the Company on the Effective Date shall not constitute grounds for a  

 

  5     termination by the Executive for Good Reason (as defined under the Prior Agreement) and  shall not entitle the Executive to any payments under Section 5(b).   (ii) Effective as of immediately following the  Transition Date, the Executive shall no longer be employed by the  Company, but shall continue to serve as Chairperson of the Board.  For the  avoidance of doubt, following the Transition Date, the   Company shall not be obligated to continue to cause the Executive to be appointed to the  Board or as Chairperson of the Board; provided, that the Company shall continue to comply  with its obligations under that certain Stockholders Agreement of the Company, as may be  amended from time to time.   (iii) At all times during the Term, the Executive (A)  shall devote   substantially all the Executive’s working time and efforts to the business and affairs of the  Company and its Affiliates; and (B) agrees to observe and comply with the Company’s  rules and policies as adopted by the Company from time to time.  The parties acknowledge  and agree that Executive’s duties, responsibilities and authority may include services for  one or more Affiliates of the Company.     3.  Compensation and Related Matters   (a) Annual Base Salary.  During the Term, the Executive shall receive a base   salary at a rate of $500,000 per annum, pro-rated for partial years of service, which shall be paid  in accordance with the customary payroll practices of the Company (the “Annual Base Salary”).   (b) Incentive Award.     (i) The Executive shall receive the following incentive awards:   (A) On, or as soon as reasonably practicable following, the Effective  Date, the Company shall grant to the Executive a stock appreciation right award (the “Initial  SAR Award”) to be settled in cash under the Company’s 2020 Incentive Award Plan (the  “Plan”) with an aggregate grant date value equal to $1,500,000; and   (B) On, or as soon as reasonably practicable following, June 1,   2023, the Company shall grant to the Executive a stock appreciation right award  (the “Subsequent SAR Award” and, together with the Initial SAR Award, the “SAR  Awards”) with an aggregate grant date value equal to $1,500,000.   (ii) Each SAR Award shall have an exercise price per share equal to the Fair  Market Value (as defined in the Plan) of the Company’s common stock on the grant date, and  shall have such other terms and conditions as are applicable to stock appreciation rights under  the Plan.  The number of shares of Company common stock subject to each SAR Award will  be determined by dividing the aggregate grant date value by the per share Black-Scholes  

 

  6     valuation as of the grant date, utilizing the same assumptions that the Company uses in the  preparation of its financial statements.   (iii) Each SAR Award shall vest in full on the third anniversary of the   grant date (irrespective of whether the Executive remains employed by the Company or  serving on the Board on such date) and shall be settled in cash upon exercise; provided,  however, that in the event the Executive’s employment or Board service is terminated by  the Company for Cause, any unvested or unexercised portion of the SAR Awards as of the  date of such termination shall be immediately forfeited for no consideration (and, for the  avoidance of doubt, to the extent the Subsequent SAR Award has not yet been granted as  of the date of such termination, the Subsequent SAR Award shall not be granted).      (iv) The terms and conditions of the SAR Awards shall be set forth in   award agreements in a form prescribed by the Company, to be entered into by the Company  and the Executive (each, an “Award Agreement”).  Except as otherwise specifically  provided in this Agreement, the SAR Awards shall be governed in all respects by the terms  of and conditions of the Plan and the applicable Award Agreement.   (c) Benefits.  During the Term, the Executive shall be eligible to participate in   employee benefit plans, programs and arrangements of the Company in accordance with their  terms, as in effect from time to time, and as are generally provided by the Company to its senior  executive officers; provided, that the Executive will not be provided with an office or other  permanent work location following the Effective Date.   (d) Business Expenses.  During the Term, the Company shall reimburse the  Executive for all reasonable, documented, out-of-pocket travel and other business expenses  incurred by the Executive in the performance of the Executive’s duties to the Company in  accordance with the Company’s applicable expense reimbursement policies and procedures.  For  the avoidance of doubt, effective as of the Effective Date, the Executive shall no longer receive  the benefit of the Executive’s Airplane Reimbursement Arrangement (as defined in the Profits Unit  Agreement).   (e) Indemnification.  During the Term and for so long thereafter as liability   exists with regard to the Executive’s activities during the Term on behalf of the Company, the  Company shall defend and indemnify the Executive (other than in connection with the Executive’s  gross negligence or willful misconduct) in accordance with the Company’s customary  indemnification policies and procedures which are applicable to the Company’s officers and  directors.    (f) Chairman Compensation.  Following the Transition Date, for so long as the  Executive remains a member of the Board, in addition to any continued vesting provided under  Section 3(b)(iii) and any severance to which the Executive may be entitled under Section 5(b), the  Executive shall receive the following compensation for his continued service on the Board:   

 

  7     (i) Notwithstanding anything to the contrary in the Company’s NonEmployee  Director Compensation Policy (the “Compensation Policy”), during the period beginning on  the Transition Date and ending on May 31, 2024, the Executive shall receive only an annual  retainer of $500,000, which shall be earned on a quarterly basis based on a calendar quarter  and shall be paid by the Company in arrears not later than the fifteenth day following the end  of each calendar quarter, pro-rated for partial calendar quarters of service based on the number  of days the Executive serves as a director in such calendar quarter and the total number of days  in such calendar quarter; and   (ii) On and after June 1, 2024, the Executive shall receive only the   compensation and benefits provided to a non-employee director of the Company under the  Compensation Policy.     For the avoidance of doubt, the termination of the Executive’s employment on the Transition Date  shall not constitute a “Termination of Service” under the Plan and the Executive shall continue to  vest in any outstanding awards held by the Executive under the Plan in accordance with their terms  for so long as the Executive remains a member of the Board (other than the SAR Awards, which,  in any event, shall continue to vest in accordance with their terms pursuant to Section 3(b)(iii)).   For the further avoidance of doubt, by executing this Agreement, the Executive acknowledges and  agrees that the compensation the Executive will receive for any service as a member of the Board  for the period beginning on the Transition Date and ending on December 31, 2023 under Section  3(f)(i) is in lieu of any compensation or benefits the Executive would otherwise be entitled to  receive under the Compensation Policy and the Executive hereby declines to receive any  compensation or benefits under the Compensation Policy during such period.   4. Termination.  The Executive’s employment hereunder may be terminated by the  Company or the Executive, as applicable, without any breach of this Agreement only under the  following circumstances:   (a) Circumstances   (i) Death.  The Executive’s employment hereunder shall  terminate   upon the Executive’s death.   (ii) Disability.  If the Executive incurs a Disability, the Company  may   give the Executive written notice of its intention to terminate the Executive’s employment.   In that event, the Executive’s employment with the Company shall terminate, effective on  the later of the thirtieth (30th) day after receipt of such notice by the Executive or the date  specified in such notice; provided that within the thirty (30) day period following receipt  of such notice, the Executive shall not have returned to full-time performance of the  Executive’s duties hereunder.   

 

  8     (iii) Termination for Cause.  The Company may terminate the  Executive’s employment for Cause.   (iv) Termination without Cause.  The Company may terminate  the Executive’s employment without Cause.   (v) Resignation for Any Reason.  The Executive may resign  from the Executive’s employment for any reason.   (vi) Occurrence of the Transition Date.  Unless earlier terminated  in   accordance with this Section 4, the Executive’s employment shall terminate automatically  upon the Transition Date.    (b) Notice of Termination.  Any termination of the Executive’s employment by   the Company or by the Executive under this Section 4 (other than a termination pursuant to Section   4(a)(i) above) shall be communicated by a written notice to the other party hereto (a “Notice of  Termination”): (i) indicating the specific termination provision in this Agreement relied upon, and   (ii) specifying a Date of Termination which, if submitted by the Executive, shall be at least thirty  (30) days following the date of such notice; provided, however, that a Notice of Termination  delivered by the Company pursuant to Section 4(a)(ii) shall not be required to specify a Date of  Termination, in which case the Date of Termination shall be determined pursuant to Section  4(a)(ii); and provided, further, that in the event that the Executive delivers a Notice of Termination  to the Company, the Company may, in its sole discretion, accelerate the Date of Termination to  any date that occurs following the date of Company’s receipt of such Notice of Termination (even  if such date is prior to the date specified in such Notice of Termination).  A Notice of Termination  submitted by the Company (other than a Notice of Termination under Section 4(a)(ii)) may provide  for a Date of Termination on the date the Executive receives the Notice of Termination, or any  date thereafter elected by the Company in its sole discretion. The failure by the Company to set  forth in the Notice of Termination any fact or circumstance which contributes to a showing of  Cause shall not preclude the Company from asserting such fact or circumstance in enforcing the   Company’s rights hereunder in connection with such Termination for Cause.  Notwithstanding the  foregoing, a termination pursuant to Section 4(a)(iii) shall be deemed to occur if following  Executive’s termination of employment for any reason the Company determines that  circumstances existing prior to such termination would have entitled the Company to terminate  Executive’s employment pursuant to Section 4(a)(iii) (disregarding any applicable cure period).      5.  Company Obligations Upon Termination of Employment   (a) In General.  Upon a termination of the Executive’s employment for any   reason, the Executive (or the Executive’s estate) shall be entitled to receive: (i) any portion of the  Executive’s Annual Base Salary through the Date of Termination not theretofore paid, (ii) any  expenses owed to the Executive under Section 3(d), (iii) any accrued but unused vacation pay owed  to the Executive in accordance with applicable law, and (iv) any amount arising from the  Executive’s participation in, or benefits under, any employee benefit plans, programs or  

 

  9     arrangements under Section 3(c), which amounts shall be payable in accordance with the terms  and conditions of such employee benefit plans, programs or arrangements.  Except as otherwise  set forth in Section 5(b) below, the payments and benefits described in this Section 5(a) shall be  the only payments and benefits payable in the event of the Executive’s termination of employment  for any reason.   (b) Severance Payments.  In the event of the Executive’s termination of   employment by the Company without Cause pursuant to Section 4(a)(iv) or as a result of the  occurrence of the Transition Date pursuant to Section 4(a)(vi), in addition to the payments and  benefits described in Section 5(a) above, the Company shall, subject to Section 21 and Section 5(c)  and subject to Executive’s execution and non-revocation of a waiver and release of claims  agreement in the Company’s customary form (a “Release”), as of the Release Expiration Date, in  accordance with Section 21(c):   (i) Continue to pay Executive’s Annual Base Salary as in effect   pursuant to the Prior Agreement immediately prior to the Effective Date (i.e., $325,000 per  annum) during the period beginning on the Date of Termination and ending on the two (2)  year anniversary of the Date of Termination (the “Severance Period”) in accordance with  the Company’s regular payroll practice as of the Date of Termination;   (ii) Pay (A) any annual cash bonus for any completed fiscal year as of   the Date of Termination that has not yet been paid as of the Date of Termination, if any,  and (B) the product of (I) two (2), multiplied by (II) a pro-rated portion of the annual cash  bonus for the year in which the Date of Termination occurs, with such proration being  based on the number of full months for which the Executive was employed during such  year prior to the Date of Termination, in each case with the applicable annual cash bonus  paid, to the extent earned, on, or at such date as is determined by the Board within 120 days  following, the last day of the fiscal year with respect to which such annual cash bonus  relates (the “Pro-Rated Bonus Amount”); provided, that, in the event the Executive  becomes entitled to payments under this Section 5(b) on or after the Effective Date, the  Pro-Rated Bonus Amount shall be calculated assuming the Executive is entitled to an  annual cash bonus targeted at $175,000, even though, for the avoidance of doubt, the  Executive will not receive any such annual cash bonus even if the Executive remains  employed through the date of payment; and   (iii) If the Executive elects to continue coverage under the Company’s   group health plan in accordance with the Consolidated Omnibus Budget Reconciliation  Act of 1985, as amended (“COBRA”), continue coverage for the Executive and any eligible  dependents under the Company group health benefit plans in which the Executive and any  dependents were entitled to participate immediately prior to the Date of Termination  (“COBRA Coverage”). In the event the Executive elects such COBRA Coverage, the  Executive shall pay to the COBRA Coverage administrator, on an after-tax basis, a  monthly amount equal to the full premium cost of the COBRA Coverage and, provided the  Executive timely submits to the Company evidence of such payments, the Company will  reimburse Executive monthly for (x) the full premium cost of the COBRA Coverage and   

 

  10     (y) an additional payment to cover estimated applicable federal, state and local income and   payroll taxes imposed on the Executive in connection with the receipt of such  reimbursements (the “COBRA Reimbursements”).  The COBRA health continuation  period under Section 4980B of the Code (the “Continuation Period”) shall run concurrently  with the period of continued coverage pursuant to this Section 5(b)(ii) and payment of the  COBRA Reimbursements by the Company shall continue until the end of the Continuation  Period; provided, however, that in the event the Executive obtains other employment that  offers group health benefits, such continuation of COBRA coverage by the Company under  this Section 5(b)(ii) shall immediately cease.   For the avoidance of doubt, the Executive shall also be entitled to acceleration in full of all unvested  Service Units (as defined in the Profits Unit Agreement) in accordance with the terms of the Profits  Unit Agreement.     (c) Breach of Restrictive Covenant Agreement.  Notwithstanding any other   provision of this Agreement, no payment shall be made or benefit provided pursuant to Section  5(b) following the date Executive first violates the Restrictive Covenant Agreement and, in the  event of such a violation, Executive shall repay to the Company any benefit provided pursuant to  Section 5(b) within ninety (90) days of such violation.   (d) Complete Severance.  The provisions of this Section 5 shall supersede in   their entirety any severance payment or benefit obligations to the Executive pursuant to the  provisions in any severance plan, policy, program or other arrangement maintained by the  Company.     6. Restrictive Covenant Agreement.  The Executive acknowledges that Executive  previously entered into that certain Restrictive Covenants Agreement with the Company dated July   6, 2020 (the “Restrictive Covenant Agreement”) and that the Executive shall continue to be bound  by the terms and conditions of the Restrictive Covenant Agreement.   7. Injunctive Relief.  The Executive recognizes and acknowledges that a breach of  the covenants contained in the Restrictive Covenant Agreement will cause irreparable damage to  the Company and its goodwill, the exact amount of which will be difficult or impossible to  ascertain, and that the remedies at law for any such breach will be inadequate.  Accordingly, the  Executive agrees that, in the event of a breach of any of the covenants contained in the Restrictive  Covenant Agreement, in addition to any other remedy which may be available at law or in equity,  the Company will be entitled to specific performance and injunctive relief.   8. Assignment and Successors.  The Company may assign its rights and obligations  under this Agreement to any entity, including any successor to all or substantially all the assets of  the Company, by merger or otherwise, and may assign or encumber this Agreement and its rights  hereunder as security for indebtedness of the Company and its Affiliates.  The Executive may not  assign the Executive’s rights or obligations under this Agreement to any individual or entity.  This  Agreement shall be binding upon and inure to the benefit of the Company, the Executive and their  

 

  11     respective successors, assigns, personnel and legal representatives, executors, administrators,  heirs, distributees, devisees, and legatees, as applicable.   9. Governing Law; Venue.  This Agreement shall be governed, construed,  interpreted and enforced in accordance with the substantive laws of the State of Delaware, without  giving effect to any principles of conflicts of law, whether of the State of Delaware or any other  jurisdiction, and where applicable, the laws of the United States, that would result in the application  of the laws of any other jurisdiction.  Each of the parties hereto agrees that any legal action or  proceeding with respect to this Agreement shall be brought exclusively in the Chancery Court of  New Castle County, Delaware or the federal courts of the United States of America for the District  of Delaware, unless the parties to any such action or dispute mutually agree to waive this provision.  By execution and delivery of this Agreement, each of the parties hereto irrevocably consents to  service of process out of any of the aforementioned courts in any such action or proceeding by the  mailing of copies thereof by registered or certified mail, postage prepaid, or by recognized express  carrier or delivery service, to the applicable party at his, her or its address referred to herein. Each  of the parties hereto irrevocably waives any objection which he, she or it may now or hereafter  have to the laying of venue of any of the aforementioned actions or proceedings arising out of or  in connection with this Agreement, or any related agreement, certificate or instrument referred to  above, brought in the courts referred to above and hereby further irrevocably waives and agrees,  to the fullest extent permitted by applicable law, not to plead or claim in any such court that any  such action or proceeding brought in any such court has been brought in any inconvenient forum.  Nothing herein shall affect the right of any party to serve process in any other manner permitted  by law.   10. Validity.  The invalidity or unenforceability of any provision or provisions of this  Agreement shall not affect the validity or enforceability of any other provision of this Agreement,  which shall remain in full force and effect.     11. Notices.  Any notice, request, claim, demand, document and other communication  hereunder to any party hereto shall be effective upon receipt (or refusal of receipt) and shall be in  writing and delivered personally or sent by telex, telecopy, or certified or registered mail, postage  prepaid, to the following address (or at any other address as any party hereto shall have specified  by notice in writing to the other party hereto):   (a) If to the Company:      GoHealth Holdings, LLC 214  West Huron Street   Chicago, Illinois 60654    Attention: Chief Legal Officer or General Counsel      Copy to:      Latham & Watkins LLP   1271 Avenue of the Americas   

 

  12     New York, New York 10020   Attn:  Bradd L. Williamson   Facsimile:  (212) 751-4864      (b) If to the Executive, at the address set forth on the signature page hereto.   12. Counterparts.  This Agreement may be executed in several counterparts, each of  which shall be deemed to be an original, but all of which together will constitute one and the same  Agreement.   13. Entire Agreement.  The terms of this Agreement (together with any other  agreements and instruments contemplated hereby or referred to herein, including, without  limitation, the Restrictive Covenant Agreement and the Resignation Letter attached hereto as  Exhibit A) is intended by the parties hereto to be the final expression of their agreement with  respect to the employment of the Executive by the Company and may not be contradicted by  evidence of any prior or contemporaneous agreement (including, without limitation, the Prior  Agreement).  The parties hereto further intend that this Agreement shall constitute the complete  and exclusive statement of its terms and that no extrinsic evidence whatsoever may be introduced  in any judicial, administrative, or other legal proceeding to vary the terms of this Agreement.   14. Amendments; Waivers.  This Agreement may not be modified, amended, or  terminated except by an instrument in writing, signed by the Executive and a duly authorized  officer of GoHealth and approved by the Board, which expressly identifies the amended provision  of this Agreement. By an instrument in writing similarly executed and approved by the Board, the  Executive or a duly authorized officer of GoHealth may waive compliance by the other party or  parties hereto with any provision of this Agreement that such other party was or is obligated to  comply with or perform; provided, however, that such waiver shall not operate as a waiver of, or  estoppel with respect to, any other or subsequent failure to comply or perform.  No failure to  exercise and no delay in exercising any right, remedy, or power hereunder shall preclude any other  or further exercise of any other right, remedy, or power provided herein or by law or in equity.   15. No Inconsistent Actions.  The parties hereto shall not voluntarily undertake or fail  to undertake any action or course of action inconsistent with the provisions or essential intent of  this Agreement.  Furthermore, it is the intent of the parties hereto to act in a fair and reasonable  manner with respect to the interpretation and application of the provisions of this Agreement.   16. Construction.  This Agreement shall be deemed drafted equally by both of the  parties hereto.  Its language shall be construed as a whole and according to its fair meaning.  Any  presumption or principle that the language is to be construed against any party hereto shall not  apply.  The headings in this Agreement are only for convenience and are not intended to affect  construction or interpretation.  Any references to paragraphs, subparagraphs, sections or  subsections are to those parts of this Agreement, unless the context clearly indicates to the contrary.   Also, unless the context clearly indicates to the contrary, (a) the plural includes the singular and  the singular includes the plural; (b) “and” and “or” are each used both conjunctively and  disjunctively; (c) “any,” “all,” “each,” or “every” means “any and all,” and “each and every”; (d)  

 

  13     ”includes” and “including” are each “without limitation”; (e) “herein,” “hereof,” “hereunder” and  other similar compounds of the word “here” refer to the entire Agreement and not to any particular  paragraph, subparagraph, section or subsection; and (f) all pronouns and any variations thereof  shall be deemed to refer to the masculine, feminine, neuter, singular or plural as the identity of the  Persons referred to may require.   17. Enforcement.  If any provision of this Agreement is held to be illegal, invalid or  unenforceable under present or future laws effective during the term of this Agreement, such  provision shall be fully severable; this Agreement shall be construed and enforced as if such illegal,  invalid or unenforceable provision had never comprised a portion of this Agreement; and the  remaining provisions of this Agreement shall remain in full force and effect and shall not be  affected by the illegal, invalid or unenforceable provision or by its severance from this Agreement.   Furthermore, in lieu of such illegal, invalid or unenforceable provision there shall be added  automatically as part of this Agreement a provision as similar in terms to such illegal, invalid or  unenforceable provision as may be possible and be legal, valid and enforceable.   18. Withholding.  The Company and its Affiliates shall be entitled to withhold from  any amounts payable under this Agreement, any federal, state, local or foreign withholding or other  taxes or charges which the Company or any of its Affiliates is required to withhold.  The Company  and its Affiliates shall be entitled to rely on an opinion of counsel if any questions as to the amount  or requirement of withholding shall arise.     19.  Absence of Conflicts; Executive Acknowledgement; Confidentiality.  The   Executive hereby represents that from and after the Effective Date the performance of the  Executive’s duties hereunder will not breach any other agreement to which the Executive is a party.   The Executive acknowledges that the Executive has read and understands this Agreement, is fully  aware of its legal effect, has not acted in reliance upon any representations or promises made by  the Company or any of its Affiliates other than those contained in writing herein, and has entered  into this Agreement freely based on the Executive’s own judgment.  The Executive agrees not to  disclose the terms or existence of this Agreement to any Person unless the Company agrees to such  disclosure in advance and in writing; provided that the Executive may, without such permission,  make such disclosures as are required by applicable law, including disclosures to taxing agencies,  and disclose the terms of this Agreement to the Executive’s attorney(s), accountant(s), tax  advisor(s), and other professional service provider(s), and to members of the Executive’s  immediate family, as reasonably necessary; provided, further, that the Executive instructs such  Person(s) that the terms of this Agreement are strictly confidential and are not to be revealed to  anyone else except as required by applicable law.   20. Survival.  The expiration or termination of the Term shall not impair the rights or  obligations of any party hereto which shall have accrued prior to such expiration or termination  (including, without limitation, pursuant to the provisions of the Restrictive Covenant Agreement  attached hereto as Exhibit A).   21. Section 409A.   

 

  14     (a) General.  The parties hereto acknowledge and agree that, to the extent   applicable, this Agreement shall be interpreted in accordance with, and incorporate the terms and  conditions required by, Section 409A.  Notwithstanding any provision of this Agreement to the  contrary, in the event that the Company determines that any amounts payable hereunder will be  immediately taxable to Executive under Section 409A, the Company reserves the right (without  any obligation to do so or to indemnify Executive for failure to do so) to (i) adopt such amendments  to this Agreement and appropriate policies and procedures, including amendments and policies  with retroactive effect, that the Company determines to be necessary or appropriate to preserve the  intended tax treatment of the benefits provided by this Agreement, to preserve the economic  benefits of this Agreement and to avoid less favorable accounting or tax consequences for the  Company and/or (ii) take such other actions as the Company determines to be necessary or  appropriate to exempt the amounts payable hereunder from Section 409A or to comply with the  requirements of Section 409A and thereby avoid the application of penalty taxes thereunder.  No  provision of this Agreement shall be interpreted or construed to transfer any liability for failure to  comply with the requirements of Section 409A from Executive or any other individual to the  Company or any of its Affiliates, employees or agents.     (b) Separation from Service under Section 409A.  Notwithstanding any   provision to the contrary in this Agreement:  (i) no amount shall be payable pursuant to Section   5(b) unless the termination of Executive’s employment constitutes a “separation from service”  within the meaning of Section 1.409A-1(h) of the Department of Treasury Regulations; (ii) for  purposes of Section 409A, Executive’s right to receive installment payments pursuant to Section  5(b) shall be treated as a right to receive a series of separate and distinct payments; and (iii) to the  extent that any reimbursement of expenses or in-kind benefits constitutes “deferred compensation”  under Section 409A, such reimbursement or benefit shall be provided no later than December 31  of the year following the year in which the expense was incurred.  The amount of expenses  reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent  year.  The amount of any in-kind benefits provided in one year shall not affect the amount of inkind  benefits provided in any other year. Notwithstanding any provision to the contrary in this   Agreement, if the Executive is deemed at the time of his separation from service to be a “specified  employee” for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed  commencement of any portion of the termination benefits to which the Executive is entitled under  this Agreement is required in order to avoid a prohibited distribution under Section  409A(a)(2)(B)(i) of the Code, such portion of the Executive’s termination benefits shall not be  provided to the Executive prior to the earlier of (x) the expiration of the six-month period measured  from the date of the Executive’s “separation from service” with the Company (as such term is  defined in the Treasury Regulations issued under Section 409A of the Code) or (y) the date of the  Executive’s death; upon the earlier of such dates, all payments deferred pursuant to this sentence  shall be paid in a lump sum to the Executive, and any remaining payments due under the  Agreement shall be paid as otherwise provided herein.    (c) Release.  Notwithstanding anything to the contrary in this Agreement, to the extent  that any payments of “nonqualified deferred compensation” (within the meaning of Section 409A)  due under this Agreement as a result of Executive’s termination of employment are subject to  

 

  15     Executive’s execution and delivery of a Release, (i) the Release shall be reasonable and drafted in  good faith (ii) the Company shall deliver the Release to Executive within ten (10) business days  following the Date of Termination, and the Company’s failure to deliver a Release prior to the  expiration of such ten (10) business day period shall constitute a waiver of any requirement to  execute a Release, (iii) if Executive fails to execute the Release on or prior to the Release  Expiration Date (as defined below) or timely revokes his acceptance of the Release thereafter,  Executive shall not be entitled to any payments or benefits otherwise conditioned on the Release,  and (iv) in any case where the Date of Termination and the Release Expiration Date fall in two  separate taxable years, any payments required to be made to Executive that are conditioned on the   Release and are treated as nonqualified deferred compensation for purposes of Section 409A shall  be made in the later taxable year.  For purposes of this Section 21(c), “Release Expiration Date”  shall mean the date that is twenty-one (21) days following the date upon which the Company timely  delivers the Release to Executive, or, in the event that Executive’s termination of employment is  “in connection with an exit incentive or other employment termination program” (as such phrase  is defined in the Age Discrimination in Employment Act of 1967), the date that is forty-five (45)  days following such delivery date.  To the extent that any payments of nonqualified deferred  compensation (within the meaning of Section 409A) due under this Agreement as a result of  Executive’s termination of employment are delayed pursuant to Section 5(b) and this Section  21(c), such amounts shall be paid in a lump sum on the first payroll date following the date that  Executive executes and does not revoke the Release (and the applicable revocation period has  expired) or, in the case of any payments subject to Section 21(c)(iv), on the first payroll period to  occur in the subsequent taxable year, if later.    22. Compensation Recovery Policy.  The Executive acknowledges and agrees that, to  the extent the Company adopts any clawback or similar policy pursuant to the Dodd-Frank Wall  Street Reform and Consumer Protection Act or otherwise, and any rules and regulations  promulgated thereunder, he shall take all action necessary or appropriate to comply with such  policy (including, without limitation, entering into any further agreements, amendments or policies  necessary or appropriate to implement and/or enforce such policy).   23. Whistleblower Protection and Trade Secrets.  Notwithstanding anything to the  contrary contained herein, nothing in this Agreement prohibits Executive from reporting possible  violations of federal law or regulation to any United States governmental agency or entity in  accordance with the provisions of and rules promulgated under Section 21F of the Securities  Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002, or any other  whistleblower protection provisions of state or federal law or regulation (including the right to  receive an award for information provided to any such government agencies).  Furthermore, in  accordance with 18 U.S.C. § 1833, notwithstanding anything to the contrary in this Agreement:  (a) Executive shall not be in breach of this Agreement, and shall not be held criminally or civilly  liable under any federal or state trade secret law (i) for the disclosure of a trade secret that is made  in confidence to a federal, state, or local government official or to an attorney solely for the purpose  of reporting or investigating a suspected violation of law, or (ii) for the disclosure of a trade secret  that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing  is made under seal; and (b) if Executive files a lawsuit for retaliation by the Company for reporting  a suspected violation of law, Executive may disclose the trade secret to Executive’s attorney, and  

 

  16     may use the trade secret information in the court proceeding, if Executive files any document  containing the trade secret under seal, and does not disclose the trade secret, except pursuant to  court order.          [Signature pages follow]  

 

          IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the date  and year first above written.                GOHEALTH                GOHEALTH, INC.                             By: /s/ Brian Farley            Name: Brian Farley             Title: Chief Legal Officer & Corporate Secretary                   PARTNERSHIP                GOHEALTH HOLDINGS, LLC         By: /s/ Brian Farley            Name: Brian Farley             Title: Chief Legal Officer & Corporate Secretary  EXECUTIVE   By:    /s/ Clint Jones   Name: Clinton Jones  ###     

 

       EXHIBIT A   Resignation Letter      June 3, 2022      GoHealth, Inc.   Attn: Brandon Cruz, Co-Chairman of the Board      Re:   Resignation as Chief Executive Officer       Mr. Cruz:      Effective, June 6, 2022 (the “Resignation Date”), I hereby resign as Chief Executive Officer of   GoHealth, Inc. (the “Company”) and its subsidiaries and affiliates.  Effective upon the Resignation Date, I  will continue working for the Company as its Executive Chairman and Co-Chair of the Board of Directors  of the Company and will continue to be an employee and director of the Company.                         Sincerely,            /s/ Clint Jones  Clinton Jonesexhibit104

  Exhibit 10.4  June 3, 2022      Brandon Cruz   [Via email]          Re:  Separation from Employment       Dear Brandon:       As we have discussed, this letter (this “Letter”) confirms that your employment with GoHealth, Inc.  (“GoHealth”) and GoHealth Holdings, LLC (the “Partnership” and, together with GoHealth and any of  the affiliates of GoHealth and the Partnership for which you provide or have provided services from time  to time and any successor(s) thereto (and for the avoidance of doubt, not including NVX Inc.), the  “Company”), which is currently governed by that certain Amended & Restated Employment Agreement by  and among you, GoHealth, the Partnership and Norvax, LLC dated July 6, 2020 (the “Employment  Agreement”), will terminate effective as of June 6, 2022 (the “Separation Date”).  Following the Separation   Date, you will continue to serve as non-executive Chair of GoHealth’s board of directors (the “Board”)  pursuant to the terms of this Letter.  All capitalized terms not defined herein shall have the meanings  assigned in the Employment Agreement.        1. Separation Date Payments.  In connection with your separation, on the Separation Date,  we will pay you (i) all earned, unpaid salary that you would have been paid through the Separation Date,  (ii) any expenses owed to you under Section 3(d) of the Employment Agreement, (iii) any accrued but  unused vacation pay owed to you pursuant to applicable law, and (iv) any amount arising from your  participation in, or benefits under, any employee benefit plans, programs or arrangements under Section  3(c) of the Employment Agreement, which amounts shall be payable in accordance with the terms and  conditions of such employee benefit plans, programs or arrangements.        2. Severance. Subject to your execution, delivery and non-revocation of the general release  of claims attached hereto as Exhibit A (the “Release”) in accordance with its terms and Section 4 hereof,  the Company will pay or provide to you the following (such payments and benefits, collectively, the  “Severance”), in each case subject to and in compliance with Section 6 hereof:      a. An amount equal to the sum of (i) continued payment of your Annual Base Salary  (at a rate of $325,000 per annum) and (ii) $350,000 (which amount is equal to 200% of your target  Annual Bonus), in each case paid out over the period beginning on June 6, 2022 and ending on   April 16, 2024 in accordance with the Company’s regular payroll practice as of the Separation Date  (“Employment Term Salary and Bonus Continuation”);      b. Continued payment of your Annual Base Salary (at a rate of $325,000 per annum)  during the period beginning on the Separation Date and ending on the two-year anniversary of the   Separation Date in accordance with the Company’s regular payroll practice as of the Separation  Date (such period, the “Severance Period,” and such payment, the “Severance Period Salary  Continuation”) (and, for the avoidance of doubt, the Severance Period shall run concurrently with  the payment period for the Employment Term Salary and Bonus Continuation and, accordingly,  you will be entitled to receive both Severance Period Salary Continuation payments and  Employment Term Salary and Bonus Continuation payments for the period beginning on the  Separation Date and ending on April 16, 2024);      c. Payment of (i) your Annual Bonus for any completed fiscal year as of the   Separation Date that has not yet been paid as of the Separation Date, if any, and (ii) the product of   

 

        (A) two (2), multiplied by (B) a pro-rated portion of your Annual Bonus for 2022, with such  proration being based on the number of full months for which you were employed during 2022 to  the Separation Date, in each case with the applicable Annual Bonus paid, to the extent earned, on,  or at such date as is determined by the Board within 120 days following, the last day of the fiscal  year with respect to which such Annual Bonus relates;      d. If you elect to continue coverage under the Company’s group health plan in  accordance with COBRA, continued coverage for you and any eligible dependents under the  Company group health benefit plans in which you and any dependents were entitled to participate  immediately prior to the Separation Date (“COBRA Coverage”). In the event you elect such  COBRA Coverage, you shall pay to the COBRA Coverage administrator, on an after-tax basis, a  monthly amount equal to the full premium cost of the COBRA Coverage and, provided you timely  submit to the Company evidence of such payments, the Company will reimburse you monthly for  (x) the full premium cost of the COBRA Coverage and (y) an additional payment to cover estimated  applicable federal, state and local income and payroll taxes imposed on you in connection with the  receipt of such reimbursements (the “COBRA Reimbursements”).  The COBRA health  continuation period under Section 4980B of the Code (the “Continuation Period”) shall run  concurrently with the period of continued coverage pursuant to this Letter and payment of the  COBRA Reimbursements by the Company shall continue until the end of the Continuation Period,  which shall continue up to the earlier of the last date on which you and any eligible dependents are  eligible for COBRA Coverage or the date you obtain other employment that offers group health  benefits, at which time such continuation of COBRA Coverage by the Company under this Letter  shall immediately cease; and      e. An amount equal to the product of (i) six (6), multiplied by (ii) the initial monthly  COBRA Reimbursement amount, paid as a cash lump sum within sixty (60) days of the Separation  Date.  Such amount is not subject to any cancelation or reduction related to your obtaining other  employment that offers group health benefits.      For the avoidance of doubt, all unvested Service Units (as defined in the Profits Unit Agreement) shall  accelerate in full on the Separation Date.  Furthermore, for the avoidance of doubt, notwithstanding anything  to the contrary herein or in any other agreement, the Company, Blizzard Parent, LLC (and its successors in  interest), and Blizzard Aggregator, LLC (and its affiliates) forever waive, and shall not otherwise exercise,  any right to repurchase the Profits Units (as defined in the Profits Unit Agreement) granted to Brandon  Cruz, including but not limited to such repurchase rights set forth in Article V of the Blizzard Parent, LLC  Profits Unit Plan, dated September 13, 2019, as amended; provided, however, that such waiver and promise  not to otherwise exercise such rights shall not apply or prevent such exercise of rights if you breach any  restrictive covenant set forth in any agreement to which you and the Company or an affiliate of the Company  are or hereafter become parties.      For purposes of Section 409A (as defined below), (i) your right to receive installment payments pursuant  to this Section 2 shall be treated as a right to receive a series of separate and distinct payments, (ii) to the  extent that any reimbursement of expenses or in-kind benefits constitutes “deferred compensation” under  Section 409A, such reimbursement or benefit shall be provided no later than December 31 of the year  following the year in which the expense was incurred, (iii) the amount of expenses reimbursed in one year  shall not affect the amount eligible for reimbursement in any subsequent year, and (iv) the amount of any  in-kind benefits provided in one year shall not affect the amount of in-kind benefits provided in any other  year.      3. Director Compensation. Following the Separation Date, you will continue to serve as a  non-executive member and Co-Chair of the Board in accordance with and subject to reelection under the  

 

     GoHealth Stockholders Agreement.  For so long as you serve as a member of the Board you shall be  compensated for such service as follows (all of which compensation shall be in addition to any Severance  provided under Section 2 of this Letter):      a. Notwithstanding anything to the contrary in the GoHealth, Inc. Non-Employee  Director Compensation Policy (“Compensation Policy”), subject to your execution, delivery and  non-revocation of a Release in accordance with its terms and Section 4 hereof:      i. For your Board service during the period beginning on the Separation Date  and ending on May 31, 2024, you will be paid an annual retainer of $500,000, which shall  be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company  in arrears not later than the fifteenth day following the end of each calendar quarter,  prorated for partial calendar quarters of service based on the number of days you serve as  a member of the Board in such calendar quarter and the total number of days in such  calendar quarter;      ii. You will receive the following incentive awards:        1. On, or as soon as reasonably practicable following, the  Separation  Date, the Company shall grant to you a stock appreciation right award (the “Initial  SAR Award”) to be settled in cash under the Company’s 2020 Incentive Award  Plan (the “Plan”) with an aggregate grant date value equal to $1,500,000.        2. On, or within thirty (30) days following, June 1, 2023, the   Company shall grant to you a stock appreciation right award (the “Subsequent  SAR Award” and, together with the Initial SAR Award, the “SAR Awards”) to be  settled in cash under the Plan with an aggregate grant date value equal to  $1,500,000.      3. Each SAR Award shall have an exercise price per share equal to  the Fair Market Value (as defined in the Plan) of the Company’s common stock on  the grant date, and shall have such other terms and conditions as are applicable to  stock appreciation rights under the Plan.  The number of shares of Company  common stock subject to each SAR Award will be determined by dividing the  aggregate grant date value by the per share Black-Scholes valuation as of the grant  date, utilizing the same assumptions that the Company uses in the preparation of  its financial statements.      4. Each SAR Award shall vest in full on the third anniversary of the  grant date (irrespective of whether you remain employed by the Company or  serving on the Board on such date) and shall be settled in cash upon exercise;  provided, however, that in the event your employment or Board service is  terminated by the Company for Cause, any unvested or unexercised portion of the  SAR Awards as of the date of such termination shall be immediately forfeited for  no consideration (and, for the avoidance of doubt, to the extent the Subsequent  SAR Award has not yet been granted as of the date of such termination, the  Subsequent SAR Award shall not be granted).      5. The terms and conditions of the SAR Awards shall be set forth in  award agreements in a form prescribed by the Company, to be entered into by the  Company and you (each, an “Award Agreement”).  Except as otherwise  specifically provided in this Agreement, the SAR Awards shall be governed in all  

 

     respects by the terms of and conditions of the Plan and the applicable Award  Agreement.      b. On and after June 1, 2024, you shall be compensated for your Board service in   accordance with the terms of the Compensation Policy.      c. For the avoidance of doubt, by signing this Letter, you acknowledge and agree   that:      i. The compensation you will receive for your service as a member of the  Board for the period beginning on the Separation Date and ending on May 31, 2024 under  Section 3(a) of this Letter, as well as any expense reimbursement as set forth in Section 3  of the Compensation Policy, is the only compensation you are entitled to receive during  such period for your service as a Director and, explicitly excluding your Severance  described in Section 2 of this Letter, is in lieu of (x) any compensation or benefits you  would otherwise be entitled to receive under the Compensation Policy and you hereby  decline to receive any compensation or benefits under the Compensation Policy during  such period and (y) any right you might otherwise have to continued payment of your  Annual Base Salary for the remainder of the Initial Employment Period under your  Employment Agreement;       ii. The termination of your employment as of the Separation Date pursuant  to this Letter will not constitute a “Termination of Service” under the Plan and you will  continue to vest in any outstanding awards held under the Plan in accordance with their  terms (and, for the avoidance of doubt, the SAR Award  shall continue to vest in accordance  with its terms pursuant to Section 3(a)(ii)(3) of this Letter); and      iii. Following the Separation Date, (A) you will not be provided with an office   or other permanent work location and (B) you will no longer receive the benefit of your  Airplane Reimbursement Arrangement (as defined in the Profits Unit Agreement).      4. Release.  You acknowledge and agree that the Company is providing you with the  Severance set forth in Section 2 and the Director Compensation set forth in Section 3 in material part in  consideration for your execution, delivery and non-revocation of the Release in accordance with its terms.   You acknowledge and agree that (a) the Company has delivered the Release to you on June 3, 2022, (b)  you have forty-five (45) days from the date the Release was delivered to you (the “Consideration Period”)  to consider and execute the Release and deliver it to the Company, (c) you have a seven (7) day period  following your delivery of the executed Release to the Company (the “Revocation Period”) to revoke your  acceptance of the Release and, if the Release is not revoked during the Revocation Period, the Release  becomes effective and irrevocable on the eighth (8th) day following your execution and delivery of the  Release (the “Release Effective Date”), (d) the Company has advised you not to execute the Release (and  it will not accept delivery of the Release from you) prior to the day following the Separation Date, and (e)  no payments will be made pursuant to Section 2 and 3(a) hereof prior to the Release Effective Date.   To  the extent that any payments due under this Letter are delayed as a result of the immediately preceding  sentence, such amounts shall be paid on the first payroll date on or following the Release Effective Date.   In the event that you do not execute and deliver the Release on or prior to the last day of the Consideration  Period or you revoke the Release during the Revocation Period, you will not receive any payments or  benefits under Section 2 or Section 3(a) hereof and you will forfeit the SAR Award.         5. Restrictive Covenants.  You acknowledge and agree that you remain bound by the  restrictive covenants set forth in that certain Restrictive Covenants Agreement with the Partnership dated  April 16, 2020 (the “Restrictive Covenant Agreement”).  These restrictive covenants have not been  

 

     impacted by your separation from employment and remain in full force and effect in accordance with their  terms.  Notwithstanding any other provision of this Letter, no payment of Severance shall be made  following the date you first violate the Restrictive Covenant Agreement and, in the event of such a violation,  you will repay to the Company any Severance received within ninety (90) days of such violation and you  will forfeit the SAR Award.       6. Section 409A.  The payments and benefits provided under this Letter are intended to be  exempt from or comply with Section 409A of the Internal Revenue Code of 1986, as amended (together  with the Department of Treasury regulations and other interpretive guidance issued thereunder, including,  without limitation, any such regulations or other guidance that may be issued after the date of this Letter,  “Section 409A”) and this Letter shall be interpreted consistently with such intent.  Notwithstanding any  provision of this Letter to the contrary, in the event that the Company determines that any amounts payable  hereunder will be immediately taxable to you under Section 409A, the Company reserves the right (without  any obligation to do so or to indemnify you for failure to do so) to (a) adopt such amendments to this Letter  and appropriate policies and procedures, including amendments and policies with retroactive effect, that  the Company determines to be necessary or appropriate to preserve the intended tax treatment of the benefits  provided by this Letter, to preserve the economic benefits of this Letter and to avoid less favorable  accounting or tax consequences for the Company and/or (b) take such other actions as the Company  determines to be necessary or appropriate to exempt the amounts payable hereunder from Section 409A or  to comply with the requirements of Section 409A and thereby avoid the application of penalty taxes  thereunder.  Notwithstanding any provision to the contrary in this Letter, if you are deemed at the time of  your separation from service to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the  Code, to the extent delayed commencement of any portion of the termination benefits to which you are  entitled under this Letter is required in order to avoid a prohibited distribution under Section  409A(a)(2)(B)(i) of the Code, such portion of your termination benefits shall not be provided to you prior  to the earlier of (x) the expiration of the six-month period measured from the date of your “separation from  service” with the Company (as such term is defined in the Treasury Regulations issued under Section 409A)  or (y) the date of your death; upon the earlier of such dates, all payments deferred pursuant to this sentence  shall be paid in a lump sum to you, and any remaining payments due under the Letter shall be paid as  otherwise provided herein.  No provision of this Letter shall be interpreted or construed to transfer any  liability for failure to comply with the requirements of Section 409A from you or any other individual to  the Company or any of its Affiliates, employees or agents.      7. This Letter, together with the Release, comprises the entire agreement between you and the  Company with respect to the subject matter hereof and thereof and supersedes any other agreement or  arrangement, including the Employment Agreement (except for those provisions of the Employment  Agreement that, by their terms, survive your separation from employment and remain in full force and  effect in accordance with their terms).  For the avoidance of doubt, you acknowledge and agree that the  payments and benefits set forth in this Letter are the only payments and benefits that you are entitled to  receive in connection with the termination of your employment and continued service on the Board.        8. This Letter shall be governed by and interpreted in accordance with the law of the State of  Illinois, without regard to the law of conflicts of that State.       9. Miscellaneous.      a. You will retain access to your bcruz@gohealth.com for so long as you remain a   member of the Board.      b. The Company shall use best efforts to remove you (in your personal capacity) and  your name from accounts held by the Company, including but not limited to bank and credit card  accounts.   

 

                  [signature page follows]       

 

     IN WITNESS WHEREOF, the parties hereto have executed this Letter on the date and year first  above written.                     GOHEALTH, INC.                               By: /s/ Brian Farley              Name: Brian Farley               Title: Chief Legal Officer & Corporate Secretary                     GOHEALTH HOLDINGS, LLC                         By: /s/ Brian Farley        By:        /s/ Brandon Cruz    Brandon Cruz        ###                                     Name: Brian Farley                        Acknowledged and agreed:          Title: Chief Legal Officer & Corporate Secretary   

 

     Exhibit A      General Release      For valuable consideration, the receipt and adequacy of which are hereby acknowledged, the  undersigned does hereby release and forever discharge the “Releasees” hereunder, consisting of GoHealth,  Inc. (the “Company”), and its partners, subsidiaries, associates, affiliates, successors, heirs, assigns, agents,  directors, officers, employees, representatives, lawyers, insurers, and all persons acting by, through, under  or in concert with them, or any of them (including, without limitation, GoHealth Holdings, LLC and Norvax,  LLC), of and from any and all manner of action or actions, cause or causes of action, in law or in equity,  suits, debts, liens, contracts, agreements, promises, liability, claims, demands, damages, losses, costs,  attorneys’ fees or expenses, of any nature whatsoever, known or unknown, fixed or contingent (hereinafter  called “Claims”), which the undersigned now has or may hereafter have against the Releasees, or any of  them, by reason of any matter, cause, or thing whatsoever arising from or relating to the undersigned’s  employment by, service to, or direct ownership of the Company from the beginning of time to the date  hereof.     The Claims released herein include, without limiting the generality of the foregoing,    a) All claims under the Age Discrimination in Employment Act (29 U.S.C. §§621 et  seq.), the Older Workers Benefit Protection Act, Title VII of the Civil Rights Act  of 1964, Sections 1981 through 1988 of Title 42 of the United States Code, the  Americans with Disabilities Act, the Family & Medical Leave Act, the Fair Labor  Standards Act, the Illinois Human Rights Act, the Illinois Wage Payment and  Collection Act, the Illinois Minimum Wage Law, and/or any other federal, state or  local law, ordinance or regulation dealing in any respect with employment and/or  discrimination, leaves of absence, return to work and/or employment  reinstatement, and/or harassment or retaliation in employment;   b) All claims for compensation, severance pay, bonus, commission, or incentive pay,  paid time off, vacation pay and/or benefits of any kind (other than any claims for  unemployment compensation benefits), including, without limitation, any claims  under the Employment Agreement;    c) All claims under any common law contract or promise, whether written or oral,  express or implied, including, without limitation under any alleged express or  implied employment contract, agreement (but in no way diminishing or impacting  the undersigned’s continuing obligations under any confidentiality-related and/or  other restrictive covenant agreements the undersigned may have signed) or other  relationship or promise of any kind, whistleblower or retaliation, tort or other  theory; and   d) All claims arising under the Employee Retirement Income Security Act of 1974,  as amended, including, without limitation any claims arising out of the Company’s  failure to provide timely notice to the undersigned regarding the undersigned’s  right to continue health care coverage.   In addition to the above-described release, the undersigned agrees and acknowledges that the  undersigned: (i) has not suffered any type of industrial or work-related injury as a result of employment  with the Company; (ii) does not possess any claim for unpaid wages, overtime, benefits or any other form  of compensation and has not filed any such claim with the Department of Labor or any other administrative  agency or court of law; (iii) has not filed any complaints, charges, applications or lawsuits against the  Company with any governmental agency or court, whether formally or informally, and whether in the  

 

     undersigned’s own name, anonymously, and/or by, though, and/or in connection with any other person or  entity; and (iv) has not assigned or otherwise transferred any rights or interests in any actual or potential  claims the undersigned might ever have asserted against the Company or any of the Releasees.      The undersigned further understands that this Agreement applies broadly to extinguish any and all  claims of the type described above, including, without limitation, any damages of any type (including,  without limitation, attorneys’ fees and costs) associated with or arising out of any such claims.  It does not,  however, include or apply to any claims that are not waivable pursuant to applicable law or that arise after  the date on which the undersigned signs this Agreement, including but not limited to claims to enforce the  terms of this Agreement.  Nothing in this Agreement shall prohibit the undersigned from reporting possible  violations of federal law or regulation to any governmental agency or entity, including but not limited to  the Securities and Exchange Commission in relation to Rule 21F, or making other disclosures that are  protected under the whistleblower provisions of federal law or regulation.  the undersigned agrees and  acknowledges that the undersigned does not need the prior authorization of the Releasees to make such  reports or disclosure, and that the undersigned is not required to notify the Releasees that the undersigned  has made such reports or disclosures.  Pursuant to 18 U.S.C. § 1833(b), the undersigned understands that  the undersigned shall not be held criminally or civilly liable under any federal or state trade secret law for  the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or  to any attorney solely for the purpose of reporting or investigating a suspected violation of law.  The  undersigned shall not be held criminally or civilly liable under any federal or state trade secret law for the  disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other  proceeding, if such filing is made under seal.  If the undersigned files a lawsuit for retaliation by the  Releasees for reporting a suspected violation of law, the undersigned may disclose the trade secret to the  undersigned’s attorney and use the trade secret information in the court proceeding, provided that the  undersigned files any document containing the trade secret under seal, and the undersigned does not  otherwise disclose the trade secret, except pursuant to court order.      In accordance with the Older Workers Benefit Protection Act of 1990, the undersigned is hereby  advised as follows:       A. The undersigned is hereby advised to consult with an attorney before signing this  Release;    B. The undersigned has at least forty-five (45) days (the “Consideration Period”) to  consider this Release including the information required by the ADEA that is  attached and made a part hereof as Appendix A before signing it.  If the  undersigned signs this Release prior to the expiration of the Consideration Period,  the undersigned waives the remainder of the Consideration Period.  The  undersigned waives the restarting of the Consideration Period in the event of any  modification of the Release, whether or not material; and    C. The undersigned has seven (7) days after signing this Release to revoke this  Release, and this Release will become effective upon the expiration of that  revocation period.     If the undersigned wishes to revoke this Release, the undersigned must deliver written notice   (which may be by email), stating the undersigned’s intent to revoke to Brian Farley, Chief Legal Officer, at  bfarley@gohealth.com, on or before 5:00 p.m. (CST) on the seventh (7th) day after the date on which the  undersigned signs this Release.  The undersigned acknowledges that if the undersigned does not sign this  Release during the Consideration Period or revokes this Release, the undersigned will not receive the   Severance (as defined in that certain letter agreement to which this release is attached (the “Letter  Agreement”) and will forfeit the SAR Award (as defined in the Letter Agreement).   

 

     The undersigned represents and warrants that there has been no assignment or other transfer of any  interest in any Claim released hereunder which the undersigned may have against Releasees, or any of them,  and the undersigned agrees to indemnify and hold Releasees, and each of them, harmless from any liability,  Claims, demands, damages, costs, expenses and attorneys’ fees incurred by Releasees, or any of them, as  the result of any such assignment or transfer or any rights or Claims under any such assignment or transfer.   It is the intention of the parties that this indemnity does not require payment as a condition precedent to  recovery by the Releasees against the undersigned under this indemnity.   The undersigned agrees that if the undersigned hereafter commences any suit arising out of, based  upon, or relating to any of the Claims released hereunder or in any manner asserts against Releasees, or any  of them, any of the Claims released hereunder, then the undersigned agrees to pay to Releasees, and each  of them, in addition to any other damages caused to Releasees thereby, all attorneys’ fees incurred by  Releasees in defending or otherwise responding to said suit or Claim.  Notwithstanding the foregoing, the  foregoing sentence shall not apply to the extent such attorneys’ fees are attributable the undersigned’s good  faith challenge to or a request for declaratory relief with respect to the validity of the waiver herein under  the ADEA.   The undersigned further understands and agrees that neither the payment of any sum of money nor  the execution of this Release shall constitute or be construed as an admission of any liability whatsoever by  the Releasees, or any of them, who have consistently taken the position that they have no liability  whatsoever to the undersigned.   The undersigned acknowledges and agrees that the undersigned is bound by the restrictive  covenants set forth in the Restrictive Covenant Agreement (as defined in the Letter Agreement).  The  undersigned hereby reaffirms the covenants, terms and conditions set forth in the Restrictive Covenant  Agreement, and acknowledges and agrees that the Covenants remain in full force and effect in accordance  with their respective terms.   This Release shall be governed by and construed in accordance with the laws of the State of Illinois,  without regard to conflicts of laws principles thereof.     For the avoidance of doubt, notwithstanding anything herein to the contrary, the undersigned shall  remain entitled to indemnification by the Company pursuant to that certain Indemnification and  Advancement Agreement by and between the undersigned and the Company.   IN WITNESS WHEREOF, the undersigned has executed this Release this ___ day of _________,  2022.   /s/ Brandon Cruz  Brandon Cruz

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]